Deutsche Bank maintained a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) and raised its price target to $115.00 (from $107.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE